Evidence map›Paper›PMID 29540256›Full record

ArticleOncology research2019

Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2.

Teng Liu, Juan Xu, Hong Li Yan, Feng Chun Cheng, Xi Jie Liu

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Frontiers in pharmacology · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Teng LiuDepartment of Pediatric Surgery, Binzhou Medical University Hospital, Binzhou City, Shandong Province, P.R. China.
Juan XuPediatric Respiration and Intensive Care Unit, Binzhou Medical University Hospital, Shandong Province, P.R. China.
Hong Li YanElectrocardiogram Room, Binzhou Medical University Hospital, Binzhou City, Shandong Province, P.R. China.
Feng Chun ChengDepartment of Pediatric Surgery, Binzhou Medical University Hospital, Binzhou City, Shandong Province, P.R. China.
Xi Jie LiuDepartment of Pediatric Surgery, Binzhou Medical University Hospital, Binzhou City, Shandong Province, P.R. China.
Binzhou University · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luteolin, which is found in plant foods, has a range of therapeutic applications. In order to examine the potential roles of luteolin in ovarian teratocarcinoma, the human ovarian teratocarcinoma cell line PA-1 was selected for functional experiments in vitro and in vivo. We demonstrated that luteolin inhibited the proliferation and colony formation of PA-1 cells in vitro. The flow cytometry results suggested that luteolin induced apoptosis of PA-1 cells in a dose-dependent manner. Immunofluorescence and qRT-PCR results showed that the expression of B-cell lymphoma-2 (Bcl-2) was decreased in luteolin-treated cells, whereas the expression of Bcl-2-associated X (Bax) was increased compared with that in the control group. In addition, luteolin inhibited the tumor growth of ovarian teratocarcinoma cells in a xenograft model. All the results suggested that luteolin induced cell apoptosis and inhibited tumor growth of PA-1 cells.

Indexed as

ApoptosisCell Line, TumorCell ProliferationFemaleHumansLuteolinOvarian NeoplasmsProto-Oncogene Proteins c-bcl-2TeratomaBCL2 protein, humanLuteolinProto-Oncogene Proteins c-bcl-2

Identifiers

PMID29540256
PMCPMC7848233
OpenAlexW2793490184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.